TNGX(Tango Therapeutics, Inc.) · 财务报表

TNGX(Tango Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$37.04M$24.86M$36.53M$42.07M$62.38M
毛利润—————
营业利润−$58.19M−$111.07M−$114.17M−$145.59M−$111.29M
净利润−$58.23M−$108.18M−$101.74M−$130.30M−$101.59M
经营现金流−$59.53M−$109.08M−$117.98M−$131.50M−$138.89M
自由现金流−$61.36M−$116.77M−$119.51M−$132.25M−$139.93M
摊薄每股收益$-0.94$-1.23$-1.08$-1.19$-0.87

Tango Therapeutics, Inc. TNGX